Your browser doesn't support javascript.
loading
DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas.
Zhu, Xizhou; Perales-Puchalt, Alfredo; Wojtak, Krzysztof; Xu, Ziyang; Yun, Kun; Bhojnagarwala, Pratik S; Bordoloi, Devivasha; Park, Daniel H; Liaw, Kevin; Bah, Mamadou A; Lieberman, Paul M; Gary, Ebony N; Patel, Ami; Weiner, David B.
Afiliación
  • Zhu X; Vaccine and Immunotherapy Center, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.
  • Perales-Puchalt A; Vaccine and Immunotherapy Center, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.
  • Wojtak K; Vaccine and Immunotherapy Center, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.
  • Xu Z; Vaccine and Immunotherapy Center, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.
  • Yun K; Vaccine and Immunotherapy Center, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.
  • Bhojnagarwala PS; Vaccine and Immunotherapy Center, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.
  • Bordoloi D; Vaccine and Immunotherapy Center, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.
  • Park DH; Vaccine and Immunotherapy Center, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.
  • Liaw K; Vaccine and Immunotherapy Center, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.
  • Bah MA; Vaccine and Immunotherapy Center, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.
  • Lieberman PM; Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA 19104, USA.
  • Gary EN; Vaccine and Immunotherapy Center, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.
  • Patel A; Vaccine and Immunotherapy Center, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.
  • Weiner DB; Vaccine and Immunotherapy Center, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.
Mol Ther Oncolytics ; 24: 218-229, 2022 Mar 17.
Article en En | MEDLINE | ID: mdl-35071745
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Mol Ther Oncolytics Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Mol Ther Oncolytics Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos